Talabostat (Val-boroPro, PT-100) Mesylate from Selleck Targets FAP to Elevate Active FGF21

Schematic diagram of FAP FGF21 signaling pathway showing enzyme inhibition and metabolic regulation
Feel free to reference this image, but please provide a link back.
Copy code to add this image to your page

Fibroblast activation protein (FAP) is a cell-surface, homodimeric serine protease belonging to the S9b prolyl oligopeptidase subfamily. Under physiological conditions, FAP hydrolyzes peptide bonds downstream of internal proline residues, targeting specific regulatory peptide hormones. Among its primary physiological substrates is Fibroblast Growth Factor 21 (FGF21), an endocrine member of the FGF superfamily critical for coordinating lipid oxidation, energy expenditure, and glucose homeostasis. Cleavage of native FGF21 near its C-terminus—specifically at the Pro171-Ala172 peptide bond—strips the molecule of its binding affinity for the obligatory co-receptor β-Klotho. Consequently, C-terminally truncated FGF21 is rendered incapable of dimerizing fibroblast growth factor receptor 1c (FGFR1c) or activating downstream intracellular signaling pathways. This post-translational proteolytic degradation yields a short plasma half-life for native FGF21, limiting its biological stability.

Targeted enzymatic inhibition offers a direct route to suppress this inactivation cascade. Talabostat (Val-boroPro, PT-100) Mesylate from Selleck is a potent, transition-state analog inhibitor containing a boronic acid pharmacophore. The molecule forms a reversible covalent complex with the active-site Ser624 residue of FAP, exhibiting slow-dissociation kinetics. Through this selective catalytic engagement, Talabostat (Val-boroPro, PT-100) Mesylate prevents substrate entry into the catalytic pocket, effectively halting the endopeptidase cleavage of endogenous FGF21. Inhibiting FAP prolongs the systemic circulation time of native FGF21, driving an accumulation of functional, intact peptide in plasma without necessitating recombinant hormone infusion.

In diet-induced obese (DIO) C57BL/6J mouse models, oral administration of the compound produces dose-dependent suppression of plasma FAP enzymatic activity. Pharmacodynamic analysis demonstrates a parallel, sustained elevation of circulating intact FGF21 levels. At physiological and supra-physiological concentrations of preserved FGF21, signaling through the β-Klotho/FGFR1c complex increases in white and brown adipose tissues. Intracellular activation manifests as transient phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and downstream stimulation of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). These intracellular changes stimulate adiponectin secretion and increase basal uncoupling protein 1 (UCP1) expression in brown adipose depots.

Over continuous multi-week dosing regimens in DIO mice, sustained target inhibition leads to marked therapeutic improvements in metabolic phenotypes. Daily caloric intake decreases significantly during the initial phase of treatment before stabilizing at a lower homeostatic set point. Body weight curves show progressive, dose-dependent reductions; dual-energy X-ray absorptiometry confirms that mass loss is driven predominantly by the depletion of visceral and subcutaneous fat depots. Lean tissue mass remains intact across treatment groups. Indirect calorimetry reveals an elevated basal metabolic rate and increased resting oxygen consumption during active nocturnal periods, occurring independently of changes in total physical locomotor activity.

Glycemic control and lipid parameters exhibit parallel improvement under FAP inhibition. Baseline fasting blood glucose and plasma insulin concentrations drop significantly in treated DIO mice relative to vehicle controls. Intraperitoneal glucose tolerance testing indicates enhanced glucose disposal kinetics, while insulin tolerance assays reflect improved peripheral insulin sensitivity. Plasma total cholesterol and triglyceride levels decrease following chronic administration. Histological evaluation of liver tissue demonstrates reduced macrovesicular lipid accumulation, indicative of attenuated hepatic steatosis.

The mechanistic necessity of the FGF21 signaling axis was confirmed using FGF21-knockout (FGF21-KO) mouse lines. When administered to DIO FGF21-KO mice, the inhibitor elicited no observable changes in body weight, food intake, plasma glucose, or energy expenditure. Furthermore, the metabolic response was attenuated when tested in lean, chow-fed wild-type mice, indicating that target inhibition exerts its primary pharmacological effects in the context of metabolic stress and elevated basal substrate turnover. These findings establish FAP as a key enzymatic regulator of endogenous FGF21 stability in vivo.


In Vivo Pharmacodynamics and Target Selectivity

Talabostat Val-boroPro, PT-100 Mesylate schematic diagram of FAP FGF21 signaling pathway in metabolic regulation
Feel free to reference this image, but please provide a link back.
Copy code to add this image to your page

FAP inhibition by talabostat mesylate blocks the proteolytic inactivation of circulating FGF21. By preserving the intact, functional C-terminal region of FGF21, the inhibitor extends its half-life and elevates active peptide concentrations. Enhanced FGF21 receptor binding in metabolic tissues reduces body weight, lowers blood glucose, and improves systemic insulin sensitivity.

Suppression of Food Intake and Visceral Adiposity

Daily oral administration of the compound produced a sustained, dose-dependent reduction in food consumption in diet-induced obese mouse models. Circulating levels of full-length FGF21 rose significantly, facilitating sustained activation of β-Klotho-FGFR1c complexes in metabolic tissues. Visceral adiposity declined substantially across all treated cohorts over a 28-day treatment period. Indirect calorimetry confirmed an elevation in night-time energy expenditure without corresponding increases in physical locomotion. Importantly, body weight trajectories in FGF21-knockout mice remained completely unaffected by treatment under identical dosing conditions. These observations verify that target engagement produces metabolic modulation strictly through endogenous FGF21 signaling preservation.

Amelioration of Hyperglycemia and Peripheral Insulin Resistance

Evaluation of glycemic parameters in treated DIO mice showed a marked drop in fasting blood glucose and plasma insulin concentrations. Glucose clearance rates during intraperitoneal glucose tolerance tests improved significantly; homeostatic model assessment of insulin resistance indicated increased peripheral tissue sensitivity. Administration of Talabostat (Val-boroPro, PT-100) Mesylate from Selleck also lowered total plasma cholesterol concentrations and reduced hepatic lipid droplet density. In contrast, lean wild-type control mice exhibited minimal alterations in metabolic markers. The physiological response to FAP inhibition appears highly specific to states of metabolic dysfunction.


References

[1]. Sánchez-Garrido MA, et al. Molecular Metabolism. 2016;5(10):1015-1024.

Resources

Related Posts